JavaScript is disabled in your browser. Please enable JavaScript to view this website.

Preliminary Screening in CRISPR-Mediated Gene Therapy

Patient-derived cells can be genetically modified using CRISPR-Cas systems (e.g., CRISPR-Cas9) for ex vivo gene editing and cell therapy applications. IDT offers both Research-Use Only (RUO) and cGMP-grade gRNAs.

Selecting cell populations that exhibit the desired edited phenotypes and screening out undesirable cells is critical and complex step in the CRISPR gene editing workflow. Flow cytometry enables high-resolution characterization of edited cell populations during gene therapy development. The Beckman Coulter Life Sciences CytoFLEX Flow Cytometer enables immunophenotyping in preclinical labs. Consider the Beckman Coulter Life Sciences CellMek SPS System for clinical labs to automate clinical flow cytometry sample preparation. Custom reagents and panels can be ordered from Beckman Coulter Life Sciences in DURA dry format for stable storage and can be loaded directly onto the Beckman Coulter Life Sciences CellMek SPS System.

To anticipate regulatory compliance when translating this workflow to a clinical setting, use the Beckman Coulter Life Sciences Navios EX flow cytometer and dry reagents available with IVD-ready certification.

SCIEX ZenoTOF 8600 System can be used to characterize sgRNA quality, integrity, and composition, supporting raw material quality control and selection of optimal candidates for downstream gene editing applications. Considerations for best candidates include post-modification off-target effects and sequencing specific target regions or loci to assess genomic stability or anomalies.

With the GxP-ready Genedata Biopharma Platform, streamline and automate management, analysis and integration of all screening data essential for CRISPR-mediated gene therapy. This includes analyzing flow cytometry, mass spectrometry and sequencing data, as well as genome-wide gRNA prediction and selection. With the software, register every step in the development of CRISPR-mediated gene therapy, from plasmid production to delivery. Track metadata in IDBS Polar Biopharma Lifecycle Management software.

Explore the path toward a CRISPR platform approach

Learn more

Preliminary Screening Products